A feasibility study to suppress myocardial [18F]-FDG uptake by pre-administration of pure caffeine

A feasibility study to suppress myocardial [18F]-FDG uptake by pre-administration of pure caffeine - PET Caffeine study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON51725

Enrollment

Registered

2022-12-22

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac inflammation

Interventions

The patients will receive one hour before the [18F]FDG injection a tablet with 200 mg of the food supplement pure caffeine.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Recent routine [18F]FDG PET/CT at Erasmus MC with inadequate myocardial [18F]FDG suppression. Signed informed consent Extra-cardiac lesions Age >= 18 years Willing to undergo the study procedures

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding History of heart failure Uncontrolled or untreated hypertension Hypersensitivity for caffeine Use of Methotrexaat, Adenosine, Stiripentol, Melatonin and/or B-blocker

Design outcomes

Primary

Measure	Time frame
To investigate the effect of pure caffeine food supplement on myocardial [18F]FDG uptake suppression and extra-cardiac image quality between the study PET/CT and the routine PET/CT in the same patient.	—

Secondary

Measure	Time frame
To monitor the safety and tolerability of pure caffeine food supplement in combination with [18F]FDG. To measure the effect of the additional caffeine on blood glucose and FFA. To gain insight in the physiological uptake pattern uptake due inadequate myocardial suppression.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 9, 2026